PT4452331T - Conjugados alvo de saponina-ácido nucleico para o tratamento de distúrbios de atrofia muscular - Google Patents

Conjugados alvo de saponina-ácido nucleico para o tratamento de distúrbios de atrofia muscular

Info

Publication number
PT4452331T
PT4452331T PT228306213T PT22830621T PT4452331T PT 4452331 T PT4452331 T PT 4452331T PT 228306213 T PT228306213 T PT 228306213T PT 22830621 T PT22830621 T PT 22830621T PT 4452331 T PT4452331 T PT 4452331T
Authority
PT
Portugal
Prior art keywords
saponin
targeted
treatment
nucleic acid
muscle wasting
Prior art date
Application number
PT228306213T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Sapreme Tech Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapreme Tech Bv filed Critical Sapreme Tech Bv
Publication of PT4452331T publication Critical patent/PT4452331T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT228306213T 2021-12-22 2022-12-20 Conjugados alvo de saponina-ácido nucleico para o tratamento de distúrbios de atrofia muscular PT4452331T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2030215 2021-12-22

Publications (1)

Publication Number Publication Date
PT4452331T true PT4452331T (pt) 2025-10-28

Family

ID=81585344

Family Applications (1)

Application Number Title Priority Date Filing Date
PT228306213T PT4452331T (pt) 2021-12-22 2022-12-20 Conjugados alvo de saponina-ácido nucleico para o tratamento de distúrbios de atrofia muscular

Country Status (11)

Country Link
US (1) US20250057971A1 (cg-RX-API-DMAC7.html)
EP (2) EP4610278A3 (cg-RX-API-DMAC7.html)
JP (1) JP2025500482A (cg-RX-API-DMAC7.html)
KR (1) KR20240121778A (cg-RX-API-DMAC7.html)
CN (1) CN118414172A (cg-RX-API-DMAC7.html)
CA (1) CA3240612A1 (cg-RX-API-DMAC7.html)
DK (1) DK4452331T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052234T3 (cg-RX-API-DMAC7.html)
IL (1) IL313728A (cg-RX-API-DMAC7.html)
PT (1) PT4452331T (cg-RX-API-DMAC7.html)
WO (1) WO2023121446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2026519131A (ja) * 2023-06-02 2026-06-11 サプリーム テクノロジーズ,ベー.フェー. 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO2018080658A1 (en) 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
KR20240172236A (ko) 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
AU2019315593B2 (en) 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US20220023433A1 (en) 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス,インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用

Also Published As

Publication number Publication date
EP4452331B1 (en) 2025-08-06
WO2023121446A1 (en) 2023-06-29
ES3052234T3 (en) 2026-01-02
EP4452331B8 (en) 2025-09-17
IL313728A (en) 2024-08-01
EP4452331A1 (en) 2024-10-30
JP2025500482A (ja) 2025-01-09
DK4452331T3 (da) 2025-09-29
CN118414172A (zh) 2024-07-30
KR20240121778A (ko) 2024-08-09
EP4610278A2 (en) 2025-09-03
EP4610278A3 (en) 2025-12-10
CA3240612A1 (en) 2023-06-29
US20250057971A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
EP4452331B8 (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
ZA201903581B (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
IL288574A (en) Oligonucleotides and methods for use in the treatment of neurological diseases
MY189979A (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
SA520411843B1 (ar) Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات
IL289245A (en) Peg-converted cystathionine beta synthase for enzyme therapy to treat homocystinuria
HUE073599T2 (hu) Módosított aminosav-származékok neurológiai betegségek és kiválasztott pszichiátriai rendellenességek kezelésére
GB202020549D0 (en) Treatment for Lysine Degradation-associated Disorders
IL282360A (en) Treatment for neurological diseases
EP4298093A4 (en) ANALOGUES FOR THE TREATMENT OF DISEASE
IL313920A (en) Treatment of heart and lung disorders
EP4025243A4 (en) CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS
IL319254A (en) History of Pyridazinone as KAT2 inhibitors for the treatment of proliferative disorders
IL313539A (en) Methods for treating neurological disorders
IL319571A (en) R-Trihexyphenidyl for the treatment of movement disorders
PL4135840T3 (pl) Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
IL304628A (en) Treatment of skin disorders
IL325459A (en) Pharmaceutical preparations for the treatment of central nervous system disorders
IL290250A (en) Targeted gene therapy to treat neurological diseases
ITTO20090432A1 (it) Procedimento per un trattamento cosmetico anti-invecchiamento mediante stimolazione dell'espressione della survivina
ZA202105229B (en) Amino acid derivatives for the treatment of inflammatory diseases
GB202100761D0 (en) Treatment of osteoarthritic pain
EP4419671A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
GB202202828D0 (en) Garment for therapeutic treatment